Want to see CH:ADXN full AI Analyst Report?
ADXN Stock Chart & Stats
CHF0.04
<CHF0.01(2.50%)
―
--
Day’s Range― - ―
52-Week RangeCHF0.03 - CHF0.09
Previous CloseN/A
VolumeN/A
Average Volume (3M)206.07K
Market Cap
CHF4.86M
Enterprise ValueCHF5.05M
Total Cash (Recent Filing)CHF937.50K
Total Debt (Recent Filing)CHF102.27K
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Aug 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding218,654,500
10 Day Avg. Volume188,431
30 Day Avg. Volume206,072
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.30
Price to Sales (P/S)35.91
P/FCF Ratio-2.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Robust Preclinical Efficacy (GABAB PAM)Consistent, cross‑species efficacy and wide safety margins materially lower technical risk for the GABAB PAM program. IND‑enabling readiness (pending funding) makes this a durable R&D asset that can attract partners or support a near‑term clinical pathway, improving long‑term program optionality.
Material Partnership And Milestone Upside (Indivior)A large, structured partner deal provides durable non‑dilutive upside if development milestones are met. Milestone and royalty economics transfer commercialization risk to a partner while creating potential multi‑year revenue streams that can substantively fund Addex or backstop financing needs.
Low Leverage Balance SheetVery low financial leverage reduces bankruptcy and refinancing risk, enhancing strategic flexibility. This durable balance sheet feature supports more favorable partnering or licensing talks and allows management to monetize assets or raise capital without high immediate solvency pressure.
Bears Say
Insufficient Cash Runway For Unpartnered ProgressionA limited cash runway constrains the company's ability to advance internal programs and forces reliance on external funding or partners. This is a durable execution risk that can delay trials, weaken negotiating leverage with partners, increase likelihood of dilutive raises, and slow value realization from R&D assets.
Persistent Negative Operating Cash FlowOngoing negative cash conversion indicates the business does not self‑fund operations or development. Even with moderated burn, sustained negative cash flow requires repeated financing, which structurally increases dilution risk and limits the firm's ability to invest in multiple programs simultaneously over the medium term.
Equity‑method Losses & Partner Dependence Hurting P&LRising equity‑method losses and dependence on partner/ spinout performance create earnings volatility and consume cash or reported profits. Long‑term, this ties Addex’s financial outcomes to third‑party execution and can complicate capital allocation, investor visibility, and ability to self‑fund priority programs.
Addex Therapeutics News
ADXN FAQ
What was Addex Therapeutics’s price range in the past 12 months?
Addex Therapeutics lowest stock price was CHF0.03 and its highest was CHF0.09 in the past 12 months.
What is Addex Therapeutics’s market cap?
Addex Therapeutics’s market cap is CHF4.86M.
When is Addex Therapeutics’s upcoming earnings report date?
Addex Therapeutics’s upcoming earnings report date is Aug 24, 2026 which is in 53 days.
How were Addex Therapeutics’s earnings last quarter?
Addex Therapeutics released its earnings results on Jun 25, 2026. The company reported -CHF0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -CHF0.01.
Is Addex Therapeutics overvalued?
According to Wall Street analysts Addex Therapeutics’s price is currently Undervalued.
Does Addex Therapeutics pay dividends?
Addex Therapeutics does not currently pay dividends.
What is Addex Therapeutics’s EPS estimate?
Addex Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Addex Therapeutics have?
Addex Therapeutics has 218,654,500 shares outstanding.
What happened to Addex Therapeutics’s price movement after its last earnings report?
Addex Therapeutics reported an EPS of -CHF0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.762%.
Which hedge fund is a major shareholder of Addex Therapeutics?
Currently, no hedge funds are holding shares in CH:ADXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Addex Therapeutics
Addex Therapeutics Ltd, a biopharmaceutical company in its development phase, specializes in the discovery, progression, and commercialization of small-molecule pharmaceutical products designed to address central nervous system (CNS) conditions. Based in Geneva, Switzerland, the firm's core research centers on identifying oral small molecule allosteric modulators that interact with G-protein coupled receptors. Its leading clinical programs feature Dipraglurant, intended for the treatment of levodopa-induced dyskinesia in Parkinson's disease and dystonia; ADX71149, targeting epilepsy and various other neurological disorders; and GABAB PAM, developed to combat addiction. Addex has established strategic licensing and collaborative partnerships with organizations including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002, the company changed its name from Addex Pharmaceuticals Ltd to its current designation in March 2012.
Options Prices
Currently, No data available
---